Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

NCT06362694 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Anaplastic Thyroid Cancer

Interventions

DRUG: Dabrafenib + Trametinib

Sponsor

Saint Petersburg State University, Russia